Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page

NIDA Home > Publications > Director's Reports > September, 2010 Index    

Director's Report to the National Advisory Council on Drug Abuse - September, 2010

Extramural Policy and Review Activities

Receipt, Referral, and Review

NIDA received 1902 applications, including both primary and dual assignments, for which the Office of Extramural Affairs (OEA) managed the programmatic referral process during this Council cycle. Of these, NIDA received the primary assignment on 1167 applications.

OEA arranged and managed 18 grant review meetings in which 371 applications were evaluated. OEA's reviews included applications in chartered, standing review committees and Special Emphasis Panels (SEPs). In addition, OEA staff arranged and managed 18 contract proposal and concept review meetings.

NIDA has one standing chartered committee, NIDA-K, which reviews Career Development applications and Institutional Training Grant applications (T32). There were also 17 Special Emphasis Panels to review grant applications for a variety of reasons:

  • Conflicts with the chartered committee
  • Behavioral Science Track Award for Rapid Transition (B/START)
  • Imaging Science Track Award for Research Transition (I/START)
  • Conference Grants (R13)
  • Loan Repayment Applications
  • Requests for Applications (RFAs)
  • Mechanism for Time-Sensitive Research Opportunities (R21)

OEA managed the following RFA reviews:

  • DA10-006/007 - Cognitive Remediation Approaches to Improve Drug Abuse Treatment Outcomes (R01 & R21)
  • DA10-012 - 2010 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
  • DA10-013 - 2010 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1)
  • DA10-014 - Systems Biology, HIV/AIDS, and Substance Abuse (R01)
  • DA10-016 - Medications Development for Cannabis-Related Disorders (R01)
  • DA10-018 - Medications Development for Substance Related Disorders (R01)
  • DA10-019 - Deep Sequencing and Analysis of Pharmacogenomic Regions: Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01)
  • OD09-108 - Extramural Loan Repayment Program for Clinical Researchers (LRP-CR)
  • OD09-109 - Extramural Pediatric Research Loan Repayment Program (LRP-PR)

Completed contract-related review activity from the Contracts Review Branch since the last Council includes:

R&D and non-R&D Contract Reviews

  • NO1DA-11-1143 - Research Dissemination

Phase II SBIR Contract Reviews

  • N44DA-10-7769 - Tool Development for New or Improved Capture Reagents
  • N44DA-10-5542 - RAPID: Risk Assessment & Prevention Involving Drug & Sexual Behaviors
  • N44DA-10-5543 - Substance Abuse Treatment Referral System

Phase I SBIR Contract Reviews

  • N43DA-11-1206 - International Activities
  • N43DA-11- 5563 - Developing Implementation Packages for Evidence-based HIV Prevention Intervention Materials for Drug Users
  • N43DA-11- 5562 - Improving Measures of Addiction
  • N43DA-11- 5564 - Developing, Validating, Refining Tools for Ecologic Momentary Assessment
  • N43DA-11-5566 - Reintegration of Criminal Offenders into the Community
  • N43DA-11-5567 - E-Technology Tools for Extending the Reach of Prevention Interventions in Rural and Remote Locations
  • N43DA-11-2223 - Development of a Device for Auto-administering Naloxone to Overcome Overdose
  • N43DA-11-2222 - Development of an Innovative Electronic Health Record (EHR) Translator Platform Facilitating Communication Among Different EHR Systems Used in Clinical Research and Treatment
  • N43DA-11-2224 - Development of a Device to Assess Hyperalgesia at the Bed Side by the Cold Pressor Test
  • N43DA-11-8897 - Development of New Methods and Approaches to Monitor Medication Compliance in Clinical Trials
  • N43DA-11-8898 - New Techniques for the Large Scale Production and Purification of Antibodies or Vaccines for the Treatment of Substance Use Disorders
  • N43DA-11-4413 - Real-time Activity as a Potential Diagnostic Marker for Pain or Drug-craving
  • N43DA-11-4414 - Video Game Targeting Relapse Prevention in Youth with Substance use Disorders
  • N43DA-11-2225 - Confirming Compliance with Experimental Pharmacotherapy Treatment of Drug Abuse

CTN Review Activities

The Data and Safety Monitoring Board met May 27, 2010 to discuss the final study report for protocol CTN 0032, HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs in the U.S.

Certificates of Confidentiality

Between April 3, 2010 and August 4, 2010, OEA processed 103 Certificate of Confidentiality applications, including 17 amendments for either extension of expiration date or protocol change.

Staff Training and Development

The OEA Symposium Series, a forum for staff training and sharing of ideas and information, continued to provide open forums for discussions and presentations that included: an open forum on NIH Guide Notices about Vertebrate Animals sections in grant applications; clarification of policies on application resubmission and determination of new application status; expansion of the provisions of the e-SNAP process; an update on Center grant and program project grant application and review processes; a Freedom of Information Act presentation by Susan Cornell, FOIA Officer and Chief FOIA Liaison, NIH; and an overview of the Cutting-Edge Basic Research Awards (CEBRA) program presented by Dr. Susan Volman, DBNBR.


Research Findings

Program Activities

Extramural Policy and Review Activities

Congressional Affairs

International Activities

Meetings and Conferences

Media and Education Activities

Planned Meetings


Staff Highlights

Grantee Honors

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. The U.S. government's official web portal